Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: J Neuropathol Exp Neurol. 2009 Sep;68(9):994–1005. doi: 10.1097/NEN.0b013e3181b44ed8

Figure 3.

Figure 3

Localization of leucine-rich repeat kinase 2 (LRRK2) in various neurodegenerative diseases. (A, B) Consecutive paired sections from the dentate gyrus (DG) of a case of Pick disease (PiD) stained with anti-paired helical filament (PHF)-tau (A) or anti-LRRK2, NB300-267 antibody (B). Arrowheads in (A) indicate tau-positive Pick bodies. (C, D) Consecutive sections from the entorhinal cortex (Ent) of a case of corticobasal degeneration (CBD) stained with anti-PHF-tau (C) or anti-LRRK2, NB300-267 antibody (D). Arrowheads in (C) highlight tau-positive pretangles. (E, F) Consecutive sections from the Ent of a case of frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) stained with anti-TAR DNA binding protein-43 (TDP-43) (E) or anti-LRRK2, NB300-267 antibody (F). Arrowheads in (E) indicate TDP-43-positive dystrophic neurites. Panels A and B, C and D, and E and F are paired consecutive sections obtained from the same affected brain region of a single case for each disorder. All scale bars = 20 μm.